ES2334555T3 - Oxidos de hierro coloidal recubiertos estables frente al calor. - Google Patents

Oxidos de hierro coloidal recubiertos estables frente al calor. Download PDF

Info

Publication number
ES2334555T3
ES2334555T3 ES00914867T ES00914867T ES2334555T3 ES 2334555 T3 ES2334555 T3 ES 2334555T3 ES 00914867 T ES00914867 T ES 00914867T ES 00914867 T ES00914867 T ES 00914867T ES 2334555 T3 ES2334555 T3 ES 2334555T3
Authority
ES
Spain
Prior art keywords
reduced
dextran
polysaccharide
complex
iron oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00914867T
Other languages
English (en)
Spanish (es)
Inventor
Ernest V. Groman
Kenneth G. Paul
Timothy B. Frigo
Howard Bengele
Jerome M. Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amag Pharmaceuticals Inc
Original Assignee
Amag Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22436002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2334555(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amag Pharmaceuticals Inc filed Critical Amag Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2334555T3 publication Critical patent/ES2334555T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Ceramic Engineering (AREA)
  • Radiology & Medical Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Iron (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Cookers (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
ES00914867T 1999-04-09 2000-03-08 Oxidos de hierro coloidal recubiertos estables frente al calor. Expired - Lifetime ES2334555T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12857999P 1999-04-09 1999-04-09
US128579P 1999-04-09

Publications (1)

Publication Number Publication Date
ES2334555T3 true ES2334555T3 (es) 2010-03-12

Family

ID=22436002

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00914867T Expired - Lifetime ES2334555T3 (es) 1999-04-09 2000-03-08 Oxidos de hierro coloidal recubiertos estables frente al calor.

Country Status (11)

Country Link
US (2) US6599498B1 (enExample)
EP (1) EP1169062B1 (enExample)
JP (2) JP5064612B2 (enExample)
AT (1) ATE446108T1 (enExample)
CY (1) CY1109527T1 (enExample)
DE (1) DE60043188D1 (enExample)
DK (1) DK1169062T3 (enExample)
ES (1) ES2334555T3 (enExample)
LU (1) LU92114I2 (enExample)
PT (1) PT1169062E (enExample)
WO (1) WO2000061191A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
DE10046514A1 (de) * 2000-09-15 2002-04-25 Diagnostikforschung Inst Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel
US6690962B2 (en) 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
WO2002046241A2 (en) * 2000-12-07 2002-06-13 Ad 'zdravlje' Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex
JP2004530513A (ja) * 2001-06-29 2004-10-07 ビオヴィトルム・アクチボラゲット 大量オートクレーブ処理の方法
WO2003057175A2 (en) 2002-01-02 2003-07-17 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
US20060014938A1 (en) * 2004-07-14 2006-01-19 Groman Ernest V Stable aqueous colloidal lanthanide oxides
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
CN101253416B (zh) 2005-05-09 2011-08-24 通用医疗公司 基于水驰豫的传感器
WO2007027843A2 (en) * 2005-08-31 2007-03-08 T2 Biosystems, Inc. Nmr device for detection of analytes involving magnetic particles
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
WO2007136413A2 (en) 2005-12-22 2007-11-29 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
PT1973549T (pt) 2006-01-06 2016-10-25 Luitpold Pharm Inc Métodos e composições para administração de ferro
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
NO329127B1 (no) * 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
EP2084550A1 (en) 2006-11-08 2009-08-05 T2 Biosystems, Inc. Nmr systems for in vivo detection of analytes
US9375495B2 (en) * 2007-04-12 2016-06-28 Industry-Academic Cooperation Foundation, Yonsei University Magnetic resonance imaging contrast agents comprising zinc-containing magnetic metal oxide nanoparticles
US20120003160A1 (en) * 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2201398A1 (en) 2007-09-28 2010-06-30 T2 Biosystems, Inc. Nmr diagnostics by means of a plastic sample container
US8519708B2 (en) * 2007-11-06 2013-08-27 T2 Biosystems, Inc. Small magnet and RF coil for magnetic resonance relaxometry
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
WO2009127045A1 (en) * 2008-04-16 2009-10-22 Stemcell Technologies Inc. Magnetic particles
AU2009308841B2 (en) 2008-10-29 2014-07-17 T2 Biosystems, Inc. NMR detection of coagulation time
US8840868B2 (en) 2009-02-04 2014-09-23 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
JP5841044B2 (ja) 2009-03-23 2016-01-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 複合糖質ワクチン
BRPI0924653B8 (pt) 2009-03-25 2021-05-25 Pharmacosmos Holding As composto de ferro-oligossacarídeo, composição e uso de deste composto
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
WO2011150212A2 (en) 2010-05-26 2011-12-01 The General Hospital Corporation Magnetic nanoparticles
US9636423B2 (en) 2010-06-02 2017-05-02 The General Hospital Corporation Optical sensor conjugates for detecting reactive oxygen and/or reactive nitrogen species in vivo
CN106176808A (zh) 2010-10-19 2016-12-07 长春纳米生技公司 金属离子纳米簇组合物
CA3155334A1 (en) 2010-10-22 2012-04-26 T2 Biosystems, Inc. NMR SYSTEMS AND METHODS FOR RAPID ANALYTE DETECTION
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CN102086232B (zh) * 2010-12-15 2012-05-23 吕辉 一种多糖铁的制备方法
US9599627B2 (en) 2011-07-13 2017-03-21 T2 Biosystems, Inc. NMR methods for monitoring blood clot formation
BR112014002986A2 (pt) 2011-08-10 2017-06-13 Adocia composição sob a forma de uma solução injetável, e formulação de dose única
WO2013043858A1 (en) 2011-09-21 2013-03-28 T2 Biosystems, Inc. Nmr methods for endotoxin analysis
WO2013078332A1 (en) 2011-11-23 2013-05-30 The General Hospital Corporation Analyte detection using magnetic hall effect
WO2013104861A1 (fr) 2012-01-09 2013-07-18 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
WO2013158281A1 (en) 2012-04-20 2013-10-24 T2 Biosystems, Inc. Compositions and methods for detection of candida species
US10274490B2 (en) 2012-06-12 2019-04-30 The General Hospital Corporation Magnetic labeling of bacteria
EP2864051B1 (en) 2012-06-25 2020-09-23 The General Hospital Corporation Sorting particles using high gradient magnetic fields
US9675640B2 (en) * 2012-08-07 2017-06-13 Southwest Research Institute Magnetic calcium phosphate nanoparticles, applications and methods of preparation thereof
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
JP2016500443A (ja) 2012-12-07 2016-01-12 ティー２ バイオシステムズ，インコーポレーテッド 強固な血餅形成をモニタリングするための方法
MX359794B (es) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
US9370202B2 (en) 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
EP3560591B1 (en) 2013-10-18 2021-02-17 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
US9566216B2 (en) 2013-11-18 2017-02-14 Southwest Research Institute Bone cements containing magnetic calcium phosphate nanoparticles
KR20150078375A (ko) 2013-12-30 2015-07-08 한화케미칼 주식회사 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물
US10898581B2 (en) 2014-01-16 2021-01-26 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
WO2016073481A1 (en) 2014-11-03 2016-05-12 The General Hospital Corporation Sorting particles in a microfluidic device
CN105597105B (zh) * 2014-11-19 2020-03-10 连云港润众制药有限公司 一种菲立莫妥的制备方法
CA2980730A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CA3011901A1 (en) 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
CN105708805A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁及其制备方法
CN105616372A (zh) * 2016-01-28 2016-06-01 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁片剂
CN105708792A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁注射液及其制备方法
TR201703251A2 (tr) 2017-03-03 2017-07-21 Berna Buelbuel Kansizliğin transdermal yoldan tedavi̇si̇nde kullanilacak demi̇r oksi̇t nanokri̇stalleri̇ i̇çeren solüsyon
CN108403716B (zh) * 2018-06-25 2021-11-05 博瑞生物医药（苏州）股份有限公司 一种超顺磁氧化铁的制备方法
SG11202108560RA (en) 2019-02-13 2021-09-29 Brigham & Womens Hospital Inc Anti-peripheral lymph node addressin antibodies and uses thereof
WO2025043086A1 (en) 2023-08-22 2025-02-27 Navinta, Llc An improved process for the preparation of solid ferumoxytol

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US2862920A (en) * 1956-06-07 1958-12-02 Ohio Commw Eng Co Ferrous carboxymethyl dextran
US3000872A (en) * 1956-06-15 1961-09-19 Ohio Commw Eng Co Preparation of carboxymethyl dextran-iron complexes
US2856398A (en) * 1956-06-15 1958-10-14 Ohio Commw Eng Co Carboxymethyl dextran-iron complexes
US2856366A (en) * 1956-07-30 1958-10-14 Ohio Commw Eng Co Stable alkaline metal solutions containing carboxymethyl dextran
US3151107A (en) * 1960-12-22 1964-09-29 Central Pharmacal Company Water-soluble iron complexes of carboxymethyl dextran
GB1019513A (en) * 1961-08-07 1966-02-09 Chemicals Inc Iron dextran complexes
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
CA1304006C (en) 1985-12-20 1992-06-23 Edwin F. Ullman Particle separation method
US5055288A (en) 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
JP2726520B2 (ja) 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
WO1991009678A1 (en) 1989-12-22 1991-07-11 Omni Quest Corporation Organo-metallic coated particles for use in separations
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
EP0783325B2 (en) 1994-09-27 2004-03-31 Amersham Health AS Contrast agent
US6165378A (en) * 1996-08-30 2000-12-26 Meito Sangyo Kabushiki Kaisha Polysaccharide derivative/magnetic metal oxide composite
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma

Also Published As

Publication number Publication date
ATE446108T1 (de) 2009-11-15
US7553479B2 (en) 2009-06-30
PT1169062E (pt) 2009-12-17
DE60043188D1 (de) 2009-12-03
EP1169062A2 (en) 2002-01-09
JP2011046752A (ja) 2011-03-10
EP1169062B1 (en) 2009-10-21
DK1169062T3 (da) 2010-01-25
WO2000061191A9 (en) 2001-06-21
LU92114I2 (fr) 2013-12-14
JP5064612B2 (ja) 2012-10-31
CY1109527T1 (el) 2014-08-13
WO2000061191A2 (en) 2000-10-19
US6599498B1 (en) 2003-07-29
US20030225033A1 (en) 2003-12-04
WO2000061191A3 (en) 2001-05-25
JP2002541218A (ja) 2002-12-03

Similar Documents

Publication Publication Date Title
ES2334555T3 (es) Oxidos de hierro coloidal recubiertos estables frente al calor.
US9555133B2 (en) Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
ES2199226T3 (es) Polimeros biocompatibles que contienen mitades diagnosticas o terapeuticas.
US4822594A (en) Contrast enhancing agents for magnetic resonance images
ES2131067T5 (es) Composicion que contiene particulas ultrafinas de oxido metalico magnetico.
JPWO1992012735A1 (ja) 磁性金属酸化物超微粒子含有組成物
HUT77993A (hu) Vastartalmú, kettős bevonatú nanorészecskék, ezek előállítása és alkalmazása a diagnosztikában, és a gyógykezelésben
EP2968619A1 (en) Enteric ct contrast material based on low-z atoms
CN102803270B (zh) 钆配位化合物、其制造方法、以及含有它的mri造影剂
JP2013535560A (ja) ヨードを含有した放射形状の高分子化合物、その製造方法及びそれを含有するｃｔ用造影剤組成物
US12447216B2 (en) Biogenic hemin-based MRI contrast agents, and compositions and methods thereof
Yang et al. Enhanced sensitivity of spectral CT imaging in vivo by using Ytterbium chelate
Wu et al. Carboxylated albumin as a dual-purpose template for fabricating gadolinium oxide nanoprobe with high metal loading and exceptional relaxivity
ES2864829T3 (es) Conjugados de tetrapirrol como agentes de contraste IRM
EP1522318A2 (en) Heat stable coated colloidal iron oxides
Lee et al. Molecular imaging of CD44-overexpressing gastric cancer in mice using T2 MR imaging
WO2020037752A1 (zh) 一种被修饰的吲哚菁绿及其制备方法和应用
Dong et al. Ultrasmall catechol-PEG-anchored ferrite nanoparticles for highly sensitive magnetic resonance angiography
CN115894301B (zh) 一种二聚化钆基t1磁共振对比造影剂及其制备方法和用途
Ataeva et al. Development of Superparamagnetic Iron Oxide Nanoparticles for Advanced MRI Contrast Enhancement
JPH09227414A (ja) 造影剤組成物
CN112891565A (zh) 锌-二甲基吡啶胺在制备诊断血栓性疾病药物中的应用